Litigation Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)

CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)

Docket		Date Filed	2018-01-10
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	6,045,501; 6,315,720; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,141,018; 7,468,363; 7,855,217; 7,959,566; 8,315,886; 8,626,531; 8,741,929
Link to Docket	External link to docket

Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-10	1		6,045,501 * 4/2000 Elsayed et al. ..............… from the In this regard, U.S. Pat. No. 6,045,501, to Elsayed et al., 65 patient, which… 6,045,501 A * 4/2000 Elsayed et al. ..........… In this regard, U.S. Pat. No. 6,045,501, to Elsayed et al., PATIENT WHILE RESTRICTING… 6,045,501 A * 4/2000 Elsayed et al. ..........	External link to document
2019-04-30	63		including in connection with proceedings on U.S. Patent No. 7,855,217; this court retains jurisdiction to enforce…211022 infringes claim numbers 1-10 of U.S. Patent No. 7,855,217 (“Asserted Claims”) (see D.I. 1): …including in connection with proceedings on U.S. Patent No. 7,855,217. 8. This court retains jurisdiction…Celgene as to Count VII (Infringement of the ‘217 Patent) of Celgene’s Complaint(D.l. l); … 5. Count VII (Infringement of the ‘217 Patent) of Celgene’s Complaint (D.I. 1) is hereby dismissed	External link to document
2019-05-08	65		BIFURCATION AND STAY WITH RESPECT TO U.S. PATENT NOS. 6,315,720, 6,561,977, 6,755,784, 8,315,886, AND 8,…REMS Patents shall be bifurcated from all claims and defenses with respect to the Remaining Patents-in-… and all other proceedings related to the REMS Patents shall be stayed; notwithstanding the foregoing,…2018 10 March 2021 2:18-cv-00461 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document